China fined two pharmaceutical companies a combined 321 million yuan ($45.4 million) for monopoly practices as the country's only suppliers of ingredients for a drug that's crucial in emergency medicine. The State Administration for Market Regulation (SAMR) fined Hong Kong-traded Grand Pharmaceutical (China) Co. Ltd. 286 million yuan and Wuhan Huihai Medicine Co. Ltd., 35 million yuan, the market regulatory agency said Sunday in a statement.

https://www.caixinglobal.com/2023-05-30/china-fines-two-chinese-drug-ingredient-suppliers-454-million-102060061.html

#caixinglobal